Moving Beyond SSRI's
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Today we have many options to treat depression: the SSRIs, Cymbalta, Effexor, Emsam, Wellbutrin, just to name a few. How do you know when to move beyond the SSRIs? When is it time to refer to a psychiatrist? What if there are no psychiatrists available to your patients? Host Dr. Leslie Lundt welcomes Dr. Stephen Ellen to discuss the new age of psychopharmacological treatment of depression.
Recommended
Details
Presenters
Overview
Today we have many options to treat depression: the SSRIs, Cymbalta, Effexor, Emsam, Wellbutrin, just to name a few. How do you know when to move beyond the SSRIs? When is it time to refer to a psychiatrist? What if there are no psychiatrists available to your patients? Host Dr. Leslie Lundt welcomes Dr. Stephen Ellen to discuss the new age of psychopharmacological treatment of depression.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Medical Industry Feature
Gene Therapy: Changing the Landscape of Hemophilia B Care
<p>Gene Therapy: Changing the Landscape of Hemophilia B Care</p>
GI Insights
Key Considerations for Second-Line PBC Treatment
<p>Key Considerations for Second-Line PBC Treatment</p>
GI Insights
Crossroads in PBC Care: When First-Line Therapy Falls Short
<p>Crossroads in PBC Care: When First-Line Therapy Falls Short</p>
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Collaborative Insights to Solve the Puzzle of Bladder Cancer</span></p>
Clinician's Roundtable
Evaluating the Safety of Ixekizumab in Psoriasis and Arthritis Patients
<p>Evaluating the Safety of Ixekizumab in Psoriasis and Arthritis Patients</p>
ACC Action Center
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
<p>Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension</p>
ACC Action Center
Fluid restriction may not be needed in chronic HF
<p>Fluid restriction may not be needed in chronic HF</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?